- Home
- ARHS vs TYRA Comparison
ARHS vs TYRA Comparison
Compare ARHS & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- TYRA
- Stock Information
- Founded
- ARHS 1986
- TYRA 2018
- Country
- ARHS United States
- TYRA United States
- Employees
- ARHS N/A
- TYRA N/A
- Industry
- ARHS Other Specialty Stores
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- TYRA Health Care
- Exchange
- ARHS Nasdaq
- TYRA Nasdaq
- Market Cap
- ARHS 1.5B
- TYRA 1.3B
- IPO Year
- ARHS 2021
- TYRA 2021
- Fundamental
- Price
- ARHS $10.82
- TYRA $22.04
- Analyst Decision
- ARHS Buy
- TYRA Strong Buy
- Analyst Count
- ARHS 11
- TYRA 4
- Target Price
- ARHS $15.18
- TYRA $29.25
- AVG Volume (30 Days)
- ARHS 1.3M
- TYRA 171.9K
- Earning Date
- ARHS 10-31-2024
- TYRA 11-05-2024
- Dividend Yield
- ARHS N/A
- TYRA N/A
- EPS Growth
- ARHS N/A
- TYRA N/A
- EPS
- ARHS 0.63
- TYRA N/A
- Revenue
- ARHS $1,275,200,000.00
- TYRA N/A
- Revenue This Year
- ARHS $0.33
- TYRA N/A
- Revenue Next Year
- ARHS $7.97
- TYRA N/A
- P/E Ratio
- ARHS $17.17
- TYRA N/A
- Revenue Growth
- ARHS N/A
- TYRA N/A
- 52 Week Low
- ARHS $7.56
- TYRA $10.38
- 52 Week High
- ARHS $19.81
- TYRA $25.14
- Technical
- Relative Strength Index (RSI)
- ARHS 36.31
- TYRA 48.19
- Support Level
- ARHS $10.19
- TYRA $21.15
- Resistance Level
- ARHS $12.82
- TYRA $23.97
- Average True Range (ATR)
- ARHS 0.63
- TYRA 1.48
- MACD
- ARHS -0.18
- TYRA -0.19
- Stochastic Oscillator
- ARHS 16.67
- TYRA 37.12
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in a number of categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and eCommerce sales channels.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).